{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '12230 El Camino Real',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.9,
 'askSize': 900,
 'averageDailyVolume10Day': 95962,
 'averageVolume': 55288,
 'averageVolume10days': 95962,
 'beta': None,
 'beta3Year': None,
 'bid': 2.78,
 'bidSize': 1400,
 'bookValue': 1.18,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.99,
 'dayLow': 2.62,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': 11.359,
 'enterpriseValue': 28772894,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '858-408-3010',
 'fiftyDayAverage': 2.734857,
 'fiftyTwoWeekHigh': 6.29,
 'fiftyTwoWeekLow': 2.11,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10214535,
 'forwardEps': -1.11,
 'forwardPE': -2.6126127,
 'fromCurrency': None,
 'fullTimeEmployees': 11,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.29198,
 'heldPercentInstitutions': 0.09494001,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/oncternal.com',
 'longBusinessSummary': 'Oncternal Therapeutics, Inc., a clinical-stage '
                        'biotechnology company, develops various product '
                        "candidates for the treatment of cancer. The company's "
                        'product pipeline includes cirmtuzumab, a monoclonal '
                        'antibody designed to inhibit the receptor tyrosine '
                        'kinase-like orphan receptor 1 (ROR1) that is being '
                        'evaluated in a Phase I/II clinical trial in '
                        'combination with ibrutinib for the treatment of '
                        'chronic lymphocytic leukemia and mantle cell '
                        'lymphoma; and TK-216, a small-molecule compound that '
                        'is designed to inhibit E26 transformation-specific '
                        'oncogene-family oncoproteins, which is being '
                        'evaluated in a Phase I clinical trial alone and in '
                        'combination with vincristine to treat Ewing sarcoma, '
                        'a rare pediatric cancer. It is also developing a '
                        'chimeric antigen receptor-T product candidate that '
                        'targets ROR1, which is currently in preclinical '
                        'development for treating hematologic cancers and '
                        'solid tumors. The company is headquartered in San '
                        'Diego, California.',
 'longName': 'Oncternal Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 57761912,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_344890993',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -36632000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.71,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858-434-1113',
 'previousClose': 2.35,
 'priceHint': 4,
 'priceToBook': 2.4576273,
 'priceToSalesTrailing12Months': 22.803755,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.99,
 'regularMarketDayLow': 2.62,
 'regularMarketOpen': 2.71,
 'regularMarketPreviousClose': 2.35,
 'regularMarketPrice': 2.71,
 'regularMarketVolume': 536095,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 19917900,
 'sharesPercentSharesOut': 0.0021,
 'sharesShort': 37212,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 24570,
 'shortName': 'Oncternal Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0029,
 'shortRatio': 0.53,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ONCT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.584,
 'twoHundredDayAverage': 3.1571941,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'fb3086bb-6779-3bd2-a1c4-93604c12e1a6',
 'volume': 536095,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.oncternal.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92130'}